RRM2 has been confirmed to be overexpressed in hepatocellular carcinoma, breast cancer, Ewing sarcoma and atypical teratoid rhabdoid tumors which is related to tumor progression and poor prognosis, and can also be used as a key marker for aggressive tumors (53–56). This evidence concerns the gene RRM2 and neoplasm.